| Description | LNK754 is a farnesyltransferase inhibitor. It is used for the treatment of cancer and Alzheimer's disease. |
| In vivo | In a mouse model of PD, APP(SL), at 6 months of age for 3 months, LNK-754 (0.9 mg/kg) significantly decreases α-synuclein plaques . |
| Synonyms | LNK754 |
| molecular weight | 479.96 |
| Molecular formula | C29H22ClN3O2 |
| CAS | 439153-64-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Keith T Gagnon. HD Therapeutics-CHDI Fifth Annual Conference. IDrugs. 2010 Apr;13(4):219-23. |